GURUFOCUS.COM » STOCK LIST » Basic Materials » Chemicals » BRAIN Biotech AG (XTER:BNN) » Definitions » Price-to-Owner-Earnings

BRAIN Biotech AG (XTER:BNN) Price-to-Owner-Earnings : (As of Jun. 08, 2024)


View and export this data going back to 2016. Start your Free Trial

What is BRAIN Biotech AG Price-to-Owner-Earnings?

As of today (2024-06-08), BRAIN Biotech AG's share price is €2.77. BRAIN Biotech AG does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for BRAIN Biotech AG's Price-to-Owner-Earnings or its related term are showing as below:


XTER:BNN's Price-to-Owner-Earnings is not ranked *
in the Chemicals industry.
Industry Median: 18.17
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-06-08), BRAIN Biotech AG's share price is €2.77. BRAIN Biotech AG's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was €-0.37. Therefore, BRAIN Biotech AG's PE Ratio for today is At Loss.

As of today (2024-06-08), BRAIN Biotech AG's share price is €2.77. BRAIN Biotech AG's EPS without NRI for the trailing twelve months (TTM) ended in was €-0.37. Therefore, BRAIN Biotech AG's PE Ratio without NRI for today is At Loss.


BRAIN Biotech AG Price-to-Owner-Earnings Historical Data

The historical data trend for BRAIN Biotech AG's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BRAIN Biotech AG Price-to-Owner-Earnings Chart

BRAIN Biotech AG Annual Data
Trend Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only - - - - -

BRAIN Biotech AG Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of BRAIN Biotech AG's Price-to-Owner-Earnings

For the Specialty Chemicals subindustry, BRAIN Biotech AG's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BRAIN Biotech AG's Price-to-Owner-Earnings Distribution in the Chemicals Industry

For the Chemicals industry and Basic Materials sector, BRAIN Biotech AG's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where BRAIN Biotech AG's Price-to-Owner-Earnings falls into.



BRAIN Biotech AG Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

BRAIN Biotech AG's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=2.77/-0.27
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BRAIN Biotech AG  (XTER:BNN) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


BRAIN Biotech AG Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of BRAIN Biotech AG's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


BRAIN Biotech AG (XTER:BNN) Business Description

Traded in Other Exchanges
Address
Darmstadter Strasse 34-36, Zwingenberg, BW, DEU, 64673
BRAIN Biotech AG is a technology company in the field of industrial biotechnology. It serves the chemical and consumer goods industries. The company develops novel biological ingredients such as enzymes, biocatalysts, and bioactive natural compounds. The company's segments include, BioProducts, BioScience and BioIncubator. Majority of the revenue is generated from its BioProducts segment which comprises of the product business with enzymes and other proteins for specific segments of the food industry. Geographically, the company generates majority of the revenue from United States of America and also has presence in other markets such as, Germany, France, United Kingdom and Netherlands.
Executives
Dr. Michael Majerus Supervisory Board
Dr. Georg Kellinghusen Supervisory Board
Michael Schneiders Board of Directors
Adriaan Moelker Board of Directors
Lukas Linnig Board of Directors

BRAIN Biotech AG (XTER:BNN) Headlines

No Headlines